Rimonabant: From RIO to BanReportar como inadecuado

Rimonabant: From RIO to Ban - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of ObesityVolume 2011 2011, Article ID 432607, 4 pages

Review ArticleSection of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Hammersmith Hospital, Imperial College London, Du Cane Road, London W12 0NN, UK

Received 2 February 2011; Accepted 3 May 2011

Academic Editor: Gianluca Iacobellis

Copyright © 2011 Amir H. Sam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.

Autor: Amir H. Sam, Victoria Salem, and Mohammad A. Ghatei

Fuente: https://www.hindawi.com/


Documentos relacionados